Abstract | BACKGROUND:
Endocannabinoids (ECs) modulate both excitatory and inhibitory components in the CNS. There is a growing body of evidence that shows ECs influence both hypothalamic orexinergic and histaminergic neurons involved in narcolepsy physiopathology. Therefore, ECs may influence sleep and sleep-wake cycle. OBJECTIVE: To evaluate EC levels in the CSF of untreated narcoleptic patients to test whether ECs are dysregulated in Narcolepsy Type 1 (NT1) and Type 2 (NT2). METHODS: RESULTS: We compared NT1 (n=6), NT2 (n=6), and healthy controls (n=6). We found significantly reduced AEA levels in NT1 patients compared to both NT2 and controls. No differences were found between AEA levels in NT2 versus controls and between 2-AG levels in all groups, although a trend toward a decrease in NT1 was evident. Finally, the CSF AEA level was related to CSF orexin levels in all subjects. CONCLUSION: We demonstrated that the EC system is dysregulated in NT1.
|
Authors | Andrea Romigi, Monica Bari, Claudio Liguori, Francesca Izzi, Cinzia Rapino, Marzia Nuccetelli, Natalia Battista, Sergio Bernardini, Diego Centonze, Nicola Biagio Mercuri, Fabio Placidi, Mauro Maccarrone |
Journal | CNS & neurological disorders drug targets
(CNS Neurol Disord Drug Targets)
Vol. 19
Issue 2
Pg. 142-147
( 2020)
ISSN: 1996-3181 [Electronic] United Arab Emirates |
PMID | 32148204
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at [email protected]. |
Chemical References |
- Arachidonic Acids
- Endocannabinoids
- Orexins
- Polyunsaturated Alkamides
- anandamide
|
Topics |
- Adult
- Arachidonic Acids
(metabolism)
- Case-Control Studies
- Endocannabinoids
(metabolism)
- Female
- Humans
- Male
- Middle Aged
- Narcolepsy
(metabolism)
- Orexins
(metabolism)
- Pilot Projects
- Polyunsaturated Alkamides
(metabolism)
- Rome
- Sleep
(physiology)
- Young Adult
|